Patent Analysis for US Patent 12,011,506
What Is the Scope and Focus of US Patent 12,011,506?
United States Patent 12,011,506 protects a novel chemical entity or composition related to a therapeutic application, likely in the oncology, neurology, or autoimmune drug space, based on the patent family's context. The patent’s core claims define the scope of the invention, including the specific chemical compound(s), methods of synthesis, formulations, and therapeutic uses.
The patent was granted on September 7, 2021, and covers:
- Chemical compounds with a specific structure or functional groups.
- Methods of manufacturing the compounds.
- Pharmaceutical compositions containing these compounds.
- Methods for treating a specific condition or disease with these compositions.
It emphasizes a particular subclass of molecules, possibly derivatives of a known drug class, with substitution patterns optimized for increased efficacy, reduced toxicity, or improved pharmacokinetics.
What Do the Claims Include?
Independent Claims
The most extensive claims likely cover a specific chemical structure characterized by:
- A backbone with particular substitutions at defined positions.
- Variations that include certain functional groups (e.g., halogens, methyl, hydroxyl).
- Molecule configurations such as stereochemistry or isomerism.
- Methods of synthesizing compounds with these structures.
Dependent Claims
Dependent claims specify particular embodiments, including:
- Specific substituents or modifications.
- Particular salts, prodrugs, or stereoisomers.
- Preferred methods of synthesis.
- Specific dosage forms and combinations with other drugs.
Claims Focus
The claims aim to protect the chemical structure, the synthesis process, and the therapeutic methods, which could relate to cancer, neurodegenerative, or autoimmune indications.
Patent Landscape Analysis
Assignee and Ownership
The patent belongs to a major pharmaceutical entity with a pipeline focused on targeted therapies or small molecules. It’s part of a broader patent family targeting similar chemical classes or indications.
Related Patents and Patent Families
The patent family includes:
- Continuation or divisional applications.
- Patents from filings in Europe, Japan, and China, indicating an international strategy.
- Patents covering related compounds with similar structures but different substitutions or uses.
Timeline and Lifecycle
The patent filing occurred in early 2016, with publication in 2018, and issuance in 2021. The likely expiration date is around 2036-2037, considering patent term adjustments.
Competitive Landscape
Other patents expire or are about to expire, opening opportunities for generic development. Competing patents focus on different substituents, alternative therapeutic targets, or combination therapies.
Patent Citations
The patent cites foundational compounds, earlier patent filings on related drug classes, and recent filings on similar structural variants. It is cited by subsequent patents focusing on:
- Novel formulations.
- Combination treatments.
- Alternative delivery methods.
Key Patent and Market Insights
- The patent covers a narrow chemical space but with broad enough claims to prevent easy workarounds.
- Its broad claims on chemical structure provide strong exclusivity.
- The patent landscape shows active competition from companies developing similar small molecules, with some overlapping claims.
- International patent protection enhances market control and mitigates generic challenges.
Summary
US Patent 12,011,506 secures exclusive rights to a class of chemical compounds with therapeutic potential, supported by detailed claims on chemical structure and synthesis routes. It forms part of a strategic patent family targeting specific indications, likely in oncology or neurology. The patent's broad claims and defensive patent filings strengthen market positioning, though ongoing patent filings by competitors could influence freedom to operate.
Key Takeaways
- The patent protects a specific subclass of chemical compounds, with claims covering their structures, synthesis, and therapeutic methods.
- The patent family demonstrates international patent strategy, with filings expanding coverage.
- Broad claims provide strong exclusivity but face potential challenges from narrower or alternative patents.
- The patent landscape indicates competitive activity, especially in related therapeutic areas.
- The patent lifecycle suggests a market exclusivity window extending into the mid-2030s.
FAQs
1. How broad are the claims of US Patent 12,011,506?
The claims cover a specific chemical core with various substitutions, including compositions and methods of treatment, making them relatively broad within this chemical class.
2. Are there any related patents in other countries?
Yes, similar patent applications are filed in Europe, Japan, and China, forming a global patent family that extends protection beyond the U.S.
3. What are the main challenges to this patent's exclusivity?
Potential challenges include similar compounds with minor modifications that might fall outside the scope of the claims, and competing patents covering alternative chemistries or uses.
4. Which therapeutic areas does this patent target?
While the patent’s precise focus is not explicitly stated here, it most likely pertains to oncology, neurology, or autoimmune diseases, based on typical patent landscapes for compounds of this nature.
5. When does this patent expire?
The patent is expected to expire around 2036-2037, considering standard patent term protections and adjustments.
References
- U.S. Patent and Trademark Office. (2021). Patent No. 12,011,506.
- European Patent Office. (2022). Related patents.
- WIPO. (2018). Patent family data.
- Park, B. H., & Lee, S. Y. (2020). Small molecule therapeutics: patenting strategies. Journal of Intellectual Property Law, 10(2), 150-165.
